Core Viewpoint - *ST Dongtong's chairman Huang Yongjun is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [2][3]. Group 1: Investigation Details - On August 6, *ST Dongtong announced that its actual controller and chairman Huang Yongjun received a notice of investigation from the CSRC due to suspected violations of information disclosure laws [3]. - The investigation is ongoing, and the company has not yet received any conclusive opinions or decisions from the CSRC [5]. Group 2: Company Operations - *ST Dongtong stated that its production and operations are currently normal, and the investigation will not affect its regular business activities [5]. - The company is committed to fulfilling its information disclosure obligations as required by regulators [5]. Group 3: Financial Performance - As of March 31, 2025, *ST Dongtong reported total revenue of 1.34 billion, a year-on-year increase of 77.41% [7]. - The company has been experiencing continuous losses since 2022, with a net profit of -0.31 billion for the latest reporting period, reflecting a year-on-year increase in losses of 58.12% [7]. - The internal control audit report for 2024 was issued with a negative opinion, highlighting significant internal control issues [6]. Group 4: Stock Information - As of the close on August 6, *ST Dongtong's stock price was 5.68 yuan per share, with a total market capitalization of 3.2 billion [8].

Core Viewpoint - *ST Dongtong faces significant risks of forced delisting due to ongoing investigations by the China Securities Regulatory Commission (CSRC) regarding information disclosure violations by its actual controller and chairman, Huang Yongjun [2][4]. Group 1: Regulatory Actions - The actual controller Huang Yongjun has been formally investigated by the CSRC for suspected violations of information disclosure laws [2][4]. - This marks the second investigation of *ST Dongtong and its key personnel by the CSRC within the year, following an earlier investigation related to false financial reporting [2][3]. - The company has received a warning of potential forced delisting if the CSRC's findings confirm significant violations as per Shenzhen Stock Exchange regulations [2][3]. Group 2: Financial Performance - In the 2024 annual report, *ST Dongtong reported revenues of 758 million yuan, a year-on-year increase of 36.09%, but incurred a net loss of 576 million yuan [3]. - For the first quarter of 2025, the company achieved revenues of 134 million yuan, with a net loss of approximately 30.54 million yuan [3]. Group 3: Audit Opinions - The 2024 annual report received an audit opinion of "unable to express an opinion," and the internal control was given a negative opinion, triggering delisting risk warnings from the Shenzhen Stock Exchange [3]. - As a result of these audit findings, the company's stock was subjected to delisting risk warnings and other risk warnings, leading to a name change from "Dongfang Tong" to "*ST Dongtong" [3]. Group 4: Company Operations - Despite the ongoing investigations, *ST Dongtong asserts that its production and operational activities remain normal and unaffected [4]. - The company commits to cooperating with the CSRC's investigation and adhering to regulatory disclosure requirements [4].

Group 1 - A total of 59 companies, executives, or shareholders have been investigated by the China Securities Regulatory Commission (CSRC) for violations of information disclosure as of August 5 this year [1] - Companies such as Dahua Intelligent, Knight Dairy, and Jiaotong University Anli have announced investigations since July, with Dahua Intelligent's stock dropping by 20% over three trading days following the announcement [1] - Violations of information disclosure include various situations such as illegal guarantees, fund occupation, changes in actual controllers, and share freezes, which are significant matters that listed companies must disclose [1] Group 2 - Tianmao Group was investigated by the CSRC for failing to disclose its 2024 annual report and 2025 Q1 report within the legal timeframe, leading to a delisting risk warning from the Shenzhen Stock Exchange [2] - Companies under investigation face risks of investor claims after administrative penalties, with most likely to receive orders for correction and fines, while some may face delisting risks due to financial fraud [2] - Stock prices of companies under investigation typically experience a short-term decline following the announcement of the investigation [2]

Core Viewpoint - Guangdong Jiaying Pharmaceutical Co., Ltd. is facing administrative penalties from the China Securities Regulatory Commission (CSRC) for failing to timely disclose related party transactions involving 220 million yuan [1][3][4] Group 1: Company Actions and Violations - Jiaying Pharmaceutical's chairman, Li Neng, is the actual controller of Hunan Yaojuneng Pharmaceutical Co., Ltd., which constitutes a related party [3] - From October 2024 to January 2025, Jiaying Pharmaceutical's subsidiary provided short-term loans to the related party, totaling 219.99 million yuan, which accounted for 28.83% of Jiaying Pharmaceutical's latest audited net assets [3][4] - The company did not follow the required procedures for related party transactions and failed to disclose these transactions in a timely manner [3][4] Group 2: Regulatory Response - The CSRC Guangdong Regulatory Bureau has determined that Jiaying Pharmaceutical's actions violate multiple provisions of the Securities Law, including failure to disclose related party transactions [4] - Proposed penalties include a warning and a fine of 1.5 million yuan for Jiaying Pharmaceutical, 1.6 million yuan for Li Neng, 1 million yuan for Yu Yongping, and 800,000 yuan for Shi Junping [5]

Core Viewpoint - The chairman of Jiaying Pharmaceutical, Li Neng, is facing penalties for misappropriating company funds shortly after taking office, highlighting governance issues within the company [1][2][3]. Group 1: Regulatory Actions - Jiaying Pharmaceutical received an administrative penalty notice from the Guangdong Securities Regulatory Bureau, with potential fines amounting to 1.5 million yuan for the company and additional fines for Li Neng and other responsible parties [1][3]. - The investigation revealed that from October 2024 to January 2025, Jiaying Pharmaceutical's subsidiary provided short-term loans to a company controlled by Li Neng, totaling 220 million yuan, which constituted 28.83% of the company's audited net assets at that time [1][3]. Group 2: Company Background - Jiaying Pharmaceutical, established in 2003 and listed in December 2007, specializes in the research, production, and sales of traditional Chinese medicine, with a focus on proprietary and patented products [8]. - The company has experienced frequent changes in its major shareholders over the years, with the most recent change occurring in 2023 when Dongfang Securities became the largest shareholder [8]. Group 3: Financial Performance - The company's financial performance has been lackluster, with net profits showing minimal growth over the past five years, including a net profit of only 15.4 million yuan in the first quarter of 2025, despite a nearly twofold increase compared to the previous year [1][8]. - From 2020 to 2024, Jiaying Pharmaceutical's net profits were 19.84 million yuan, 1.48 million yuan, 43.93 million yuan, 34.32 million yuan, and 20.61 million yuan, indicating overall stagnant performance [8][9].

Core Viewpoint - Jia Ying Pharmaceutical is facing administrative penalties from the China Securities Regulatory Commission for violations related to information disclosure and improper related-party transactions [3][4] Group 1: Regulatory Actions - The company and its key personnel, including Chairman Li Neng, General Manager You Yongping, and former CFO Shi Junping, received a notice of administrative penalties for failing to disclose related-party transactions properly [3][4] - The Guangdong Regulatory Bureau plans to impose a fine of 1.5 million yuan on Jia Ying Pharmaceutical and varying fines on the individuals involved, with Li Neng facing a fine of 160,000 yuan [4] Group 2: Related-Party Transactions - Between October 2024 and January 2025, Jia Ying Pharmaceutical's subsidiary provided short-term loans to its related party, Hunan Yao Juneng, totaling 220 million yuan, which accounted for 28.83% of the company's audited net assets at that time [3] - The transactions were not conducted in accordance with the required approval procedures and were not disclosed in a timely manner [3] Group 3: Company Background - Jia Ying Pharmaceutical, established in 2003 and listed on the Shenzhen Stock Exchange in 2007, specializes in the research, production, and sales of traditional Chinese medicine [6] - The company has total assets exceeding 1 billion yuan and a market capitalization of nearly 3 billion yuan [6] Group 4: Financial Performance - In 2024, Jia Ying Pharmaceutical reported revenue of 376 million yuan, a year-on-year decrease of 29.46%, and a net profit of 20.61 million yuan, down 39.94% [7] - In the first quarter of 2025, the company saw a revenue increase of 28.83% year-on-year, reaching 122 million yuan, and a net profit increase of 197.23%, totaling 15.40 million yuan [7]

一、《行政处罚事先告知书》的具体内容 广东嘉应制药股份有限公司、李能、游永平、史俊平： 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会保证本公告内容的真实、准确和完整，不存在虚假记载、误导性陈述或者重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）于 2025年5月28日收到中国证券监督管理委员会（以下 简称"中国证监会"）下发的《立案告知书》（编号：证监立案字0062025010号）。因公司涉嫌信息披露 违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决 定对公司立案。具体内容详见公司于2025年5月29日披露在《证券时报》《中国证券报》《证券日报》 和巨潮资讯网（http://www.cninfo.com.cn）的《关于收到中国证券监督管理委员会立案告知书的公告》 （公告编号：2025-033）。 2025年8月1日，公司及相关责任人李能先生（现任董事长）、游永平先生（现任董事、总经理）、史俊 平先生（时任财务总监）收到中国证监会广东监管局下发的《行政处罚事先告知书》（广东证监处罚字 [2025]10号），现将具体内容公告如下： 广东嘉应制药 ...

涉嫌信息披露违法违规 嘉应制药 《行政处罚事先告知书》显示，嘉应制药董事长李能是湖南药聚能医药有限公司（下称"药聚能"）的实 际控制人，药聚能构成嘉应制药的关联方。2024年10月至2025年1月期间，因药聚能存在短期资金需 求，嘉应制药的子公司嘉应制药（湖南）有限公司（下称"湖南嘉应"）以月初转出、月末转回的方式， 向药聚能提供短期资金拆借，单笔发生额在4万元至5999万元之间。其中，2024年度合计转出1.7亿元； 2025年1月转出5000万元，并均于当月转回，累计涉及金额为2.2亿元，占嘉应制药当时最近一期经审计 净资产的28.83%。 "上述关联方非经营性资金往来未依法履行关联交易审议程序，也未按规定及时披露。"《行政处罚事先 告知书》称，上述有关违法事实，有嘉应制药相关公告、记账凭证、借款合同、银行回单、相关人员询 问笔录等证据证明。 《行政处罚事先告知书》称，李能作为嘉应制药董事长，组织相关人员向药聚能转账，是对嘉应制药上 述信息披露违法违规行为直接负责的主管人员。游永平作为嘉应制药的总经理及湖南嘉应的总经理，负 责嘉应制药和湖南嘉应的整体运营和管理，未勤勉尽责，是嘉应制药上述信息披露违法违规行 ...

Core Viewpoint - Jia Ying Pharmaceutical has been fined a total of 4.9 million yuan due to violations of information disclosure laws, which has raised concerns about its governance and financial practices [3][5][6]. Group 1: Regulatory Actions - Jia Ying Pharmaceutical and related responsible persons received a total fine of 4.9 million yuan from the China Securities Regulatory Commission (CSRC) [3]. - The company’s subsidiary, Hunan Jia Ying, provided a total of 220 million yuan in short-term loans to a company controlled by its actual controller, Li Neng, without proper disclosure [3][6]. - The fines include 150,000 yuan for the company, 1.6 million yuan for Li Neng, 1 million yuan for the general manager, and 800,000 yuan for the former financial director [3]. Group 2: Financial Performance - Jia Ying Pharmaceutical has experienced a decline in revenue and net profit over the past two years, with 2024 revenue dropping to 376 million yuan, a decrease of 29.46% year-on-year, and net profit falling to 20.61 million yuan, down 39.94% [14]. - The company reported a significant drop in operating cash flow, turning negative at -11.83 million yuan, a year-on-year decline of 193.73% [16]. - Accounts receivable surged by 40.48% to 132 million yuan, indicating potential liquidity issues [17]. Group 3: Management Changes - The company has seen frequent changes in its executive team, with the resignation of key personnel including the secretary and financial director earlier this year [12]. - Li Neng took over as chairman of Jia Ying Pharmaceutical in August 2024, shortly before the financial misconduct occurred [7][8]. Group 4: Market Reaction - Following the announcement of the regulatory penalties, Jia Ying Pharmaceutical's stock rose by 3.12%, with a total market capitalization of 3.527 billion yuan as of August 1 [1]. - Since June 20, the stock has experienced an upward trend, with a cumulative increase of over 16% [1].

证券代码：002198 证券简称：嘉应制药 公告编号：2025-042 广东嘉应制药股份有限公司 本公司及董事会保证本公告内容的真实、准确和完整，不存在虚假记载、误导 性陈述或者重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）于 2025 年 5 月 28 日收 到中国证券监督管理委员会（以下简称"中国证监会"）下发的《立案告知书》 （编号：证监立案字 0062025010 号）。因公司涉嫌信息披露违法违规，根据《中 华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会 决定对公司立案。具体内容详见公司于 2025 年 5 月 29 日披露在《证券时报》 《中 国证券报》《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）的《关于收 到中国证券监督管理委员会立案告知书的公告》（公告编号：2025-033）。 生（现任董事、总经理）、史俊平先生（时任财务总监）收到中国证监会广东监 管局下发的《行政处罚事先告知书》（广东证监处罚字[2025]10 号），现将具体 内容公告如下： 一、《行政处罚事先告知书》的具体内容 广东嘉应制药股份有限公司、李能、游永平、史俊平： ...